Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dr John LaMattina Joins Ziarco as Strategic Advisor

Published: Tuesday, March 19, 2013
Last Updated: Tuesday, March 19, 2013
Bookmark and Share
Dr LaMattina will provide input on the company's corporate, R&D strategy and growth plans.

Ziarco has appointed pharma leader and former President of Pfizer Global R&D, Dr John L. LaMattina as Strategic Advisor. His role at Ziarco will be to provide input on the company's corporate, R&D strategy and growth plans.

Commenting on his appointment, Dr LaMattina said: "Ziarco has amassed an excellent portfolio of early drug candidates with great potential. I am very much looking forward to working with the Ziarco team to convert these assets into valued new medicines."

Ziarco’s CEO, Dr Mike Yeadon, commented: "We are delighted that John is joining the team as a Strategic Advisor. Under his inspirational leadership during his long career at Pfizer, not only were several excellent medicines discovered and developed, but many of what are now industry-recognized R&D best-practises were established, as were many future leaders also. His expertise will be invaluable to use as we drive our portfolio of preclinical and clinical programs forward."

John L. LaMattina, PhD
Dr. LaMattina is a Senior Partner at PureTech and was previously President, Pfizer Global Research and Development and Senior Vice President, Pfizer Inc.

During Dr. LaMattina’s leadership tenure Pfizer advanced a number of important new medicines including Chantix, Selzentry, Lyrica, Inlyta, Xalkori and Xaljenz.

He is the author of numerous scientific publications and U.S. patents. In addition, Dr. LaMattina is the author of “Drug Truths: Dispelling the Myths About Pharma R&D” and “Devalued & Distrusted - Can the pharma industry restore its broken image.”

Dr. LaMattina serves on the Board of Directors of Ligand Pharmaceuticals, Vedanta and Gelesis, and is a member of the Scientific Advisory Board of Trevena Pharmaceuticals.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Lemon Juice and Human Norovirus
Citric acid may prevent the highly contagious norovirus from infecting humans, scientists discovered from the German Cancer Research Center.
Study Backs Flu Vaccinations for Elderly
Brown University researchers found vaccines well matched to the year’s flu strain significantly reduce deaths and hospitalizations compared to when the match is poor, suggesting that vaccination indeed makes a difference.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Protein Found to Play a Key Role in Blocking Pathogen Survival
Calprotectin fends off microbial invaders by limiting access to iron, an important nutrient.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!